Cargando…
Microbiome-derived metabolome as a potential predictor of response to cancer immunotherapy
Cancer immunotherapy with checkpoint blockade has become standard of care treatment for numerous cancer types. Despite this, robust predictive biomarkers are lacking. There is increasing evidence that the host microbiome is a predictor of immunotherapy response, although the optimal host microbiome...
Autores principales: | Malczewski, Agnieszka Beata, Navarro, Severine, Coward, Jermaine IG, Ketheesan, Natkunam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604862/ https://www.ncbi.nlm.nih.gov/pubmed/33127655 http://dx.doi.org/10.1136/jitc-2020-001383 |
Ejemplares similares
-
Enhancing Checkpoint Inhibitor Therapy in Solid Tissue Cancers: The Role of Diet, the Microbiome & Microbiome-Derived Metabolites
por: Malczewski, Agnieszka Beata, et al.
Publicado: (2021) -
A murine model of tuberculosis/type 2 diabetes comorbidity for investigating the microbiome, metabolome and associated immune parameters
por: Sathkumara, Harindra D., et al.
Publicado: (2021) -
Categorization of metabolome in bacterial systems
por: Kolhi, Shweta, et al.
Publicado: (2012) -
Rethinking the immunotherapy numbers game
por: Bekker, Rebecca A, et al.
Publicado: (2022) -
The microbiome mutiny hypothesis: can our microbiome turn against us when we are old or seriously ill?
por: Rózsa, Lajos, et al.
Publicado: (2015)